Research programme: anti-TIRC7 modulators - GenPat77/MedImmune

Drug Profile

Research programme: anti-TIRC7 modulators - GenPat77/MedImmune

Alternative Names: Anti-TIRC7 modulators research programme – GenPat77/MedImmune

Latest Information Update: 21 Jun 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GenPat77 Pharmacogenetics
  • Class Biological proteins; Small molecules
  • Mechanism of Action T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Autoimmune disorders

Most Recent Events

  • 19 Jun 2007 MedImmune has been acquired by AstraZeneca
  • 31 Dec 2005 Discontinued - Preclinical for Autoimmune disorders in Germany (unspecified route)
  • 15 Feb 2005 A preclinical study has been added to the Immunological Disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top